Pesquisas alternativas:
doses developing » does developing (Expandir a Pesquisa), costs developing (Expandir a Pesquisa), masses developing (Expandir a Pesquisa)
cases developing » case developing (Expandir a Pesquisa), masses developing (Expandir a Pesquisa), costs developing (Expandir a Pesquisa)
care developing » late developing (Expandir a Pesquisa), care development (Expandir a Pesquisa)
developing type » developing novel (Expandir a Pesquisa)
drug care » drugs care (Expandir a Pesquisa), drug card (Expandir a Pesquisa), drug case (Expandir a Pesquisa)
doses developing » does developing (Expandir a Pesquisa), costs developing (Expandir a Pesquisa), masses developing (Expandir a Pesquisa)
cases developing » case developing (Expandir a Pesquisa), masses developing (Expandir a Pesquisa), costs developing (Expandir a Pesquisa)
care developing » late developing (Expandir a Pesquisa), care development (Expandir a Pesquisa)
developing type » developing novel (Expandir a Pesquisa)
drug care » drugs care (Expandir a Pesquisa), drug card (Expandir a Pesquisa), drug case (Expandir a Pesquisa)
1
Por Millán Núñez-Cortés, Jesús, Cases Amenós, Aleix, Ascaso Gimilio, Juan Francisco, Barrios Alonso, Vivencio, Pascual Fuster, Vicente, Pedro-Botet Montoya, Juan Carles, Pintó Sala, Xavier, Serrano Cumplido, Adalberto
Publicado no Am J Cardiovasc Drugs (2016)
“... factors are the drug characteristics (potency, dose), patient characteristics (kidney function, age...”Publicado no Am J Cardiovasc Drugs (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
3
“... risks we considered the relevance to AD drug development of the following factors: (1) effective dosing...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Regev, Arie, Seeff, Leonard B., Merz, Michael, Ormarsdottir, Sif, Aithal, Guruprasad P., Gallivan, Jim, Watkins, Paul B.
Publicado em 2014
“... (DILI) during drug development. DILI may resemble almost any type of liver disease, and often presents a...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
Por Takahashi, Traci A., Merrill, Joseph O., Boyko, Edward J., Bradley, Katharine A.
Publicado em 2003
“... drug users (IDUs) is estimated to be between 21% and 32%. Little is known regarding the health care...”Publicado em 2003
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
Por Reisinger, Stephanie J, Ryan, Patrick B, O'Hara, Donald J, Powell, Gregory E, Painter, Jeffery L, Pattishall, Edward N, Morris, Jonathan A
Publicado em 2010
“... eras aggregate diagnoses that occur within a single episode of care. Drugs and conditions from source...”Publicado em 2010
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
Por Kane-Gill, Sandra L., Visweswaran, Shyam, Saul, Melissa I., Wong, An-Kwok Ian, Penrod, Louis E., Handler, Steven M.
Publicado em 2011
“... be considered when developing methods to detect adverse drug reactions as part of intensive care unit patient...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
9
Por Hutschemaekers, Giel J.M.
Publicado em 2003
Assuntos:
“...Projects and Developments...”Publicado em 2003
Obter o texto integral
Obter o texto integral
Artigo
10
Por Ahmed, Zuhayer, Hafez, M. A., Bari, M. A., Akhter, Jesmin
Publicado no Int J Basic Clin Pharmacol (2016)
“... of the world before developing & marketing any new drug....”Publicado no Int J Basic Clin Pharmacol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
11
“... been developed based on this scenario. After implementing the new scheduling template, 22.5% more...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Margulies, Susan S., Kilbaugh, Todd, Sullivan, Sarah, Smith, Colin, Propert, Kathleen, Byro, Melissa, Saliga, Kristen, Costine, Beth A., Duhaime, Ann‐Christine
Publicado no Brain Pathol (2015)
“... and uses two post‐TBI delays to drug administration. Cyclosporin A (CsA) was used as a case study in our...”Publicado no Brain Pathol (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
“... dependent on the drug’s pharmacological action and dose. Common Type B reactions seen in clinical practice...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
“... of injection drug users (IDUs) by type of health care setting, which can inform development of tailored...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
Por Alexey Zharov, Rostislav Smachylo, Alexandr Pochuev, Yulia Chernykova, Darya Bezvesilnaya, Tetiana Kozlova, Nikita Chernyayev
Publicado em 2020-06-01
Assuntos:
“...type ii diabetes mellitus...”Publicado em 2020-06-01
Obter o texto integral
Artigo
16
“...BACKGROUND: Poisoning and drug overdose (DO) are important health problems in developing countries...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Roche, Jo C, Morris-Stiff, Gareth, Champ, Carrie, Williams, Geraint T, Lewis, Michael H
Publicado em 2008
Assuntos:
“...Case Report...”Publicado em 2008
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Goswami, Avranil, Chakraborty, Urmita, Mahapatra, Tanmay, Mahapatra, Sanchita, Mukherjee, Tapajyoti, Das, Shibali, Das, Aritra, Dey, Subir Kumar, Ray, Sudhin, Bhattacharya, Basudev, Pal, Nishith Kumar
Publicado em 2014
“... diagnostic findings, patient types (based on treatment outcomes), drug resistance and socio-demographic...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
Por Coenen, Martin, Hinze, Annette Viktoria, Mengel, Martin, Fuhrmann, Christine, Lüdenbach, Bastian, Zimmermann, Julian, Dykstra, Verena, Fimmers, Rolf, Viviani, Roberto, Stingl, Julia, Holdenrieder, Stefan, Müller, Marcus, Hartmann, Gunther, Coch, Christoph
Publicado no BMC Pharmacol Toxicol (2015)
“... the dose steps within the first-in-human trial with a newly developed RIG-I ligand. Thus, ResI is a...”Publicado no BMC Pharmacol Toxicol (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Por Ogiso, Kazuma, Koriyama, Nobuyuki, Akao, Ayako, Otsuji, Mayumi, Goto, Takahiko, Fujisaki, Natsuko, Minobe, Machiko, Kinowaki, Mayumi, Matsuki, Shigeru
Publicado no J Diabetes Metab Disord (2015)
Assuntos:
“...Case Report...”Publicado no J Diabetes Metab Disord (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo